Page - 86 - in Cancer Nanotheranostics - What Have We Learnd So Far?

Conniotet al. Nanocarriers for immunecell targetingand tracking (PhD Grant SFRH/BD/87150/2012 to João Conniot, SFRH/BD/64295/2009 to Joana M. Silva PTDC/SAU- FAR/119389/2010 and Pest-OE/SAU/UI4013/2011). Funding from theUKEngineering&Physical Sciences ResearchCouncil (EPSRC) for theEPSRCCentre for InnovativeManufacturing in EmergentMacromolecularTherapies isgratefullyacknowledged. Financial support fromtheconsortiumof industrial andgovern- mental users is also acknowledged. The authors have no other relevant affiliations or financial involvementwith any organiza- tion or entity with a financial interest or financial conflict with thesubjectmatterormaterialsdiscussed inthemanuscript. SUPPLEMENTARYMATERIAL The Supplementary Material for this article can be found online at: http://www.frontiersin.org/journal/10.3389/fchem. 2014.00105/abstract REFERENCES Abraham,S.A.,Waterhouse,D.N.,Mayer, L.D.,Cullis, P.R.,Madden,T.D., and Bally,M.B. (2005).The liposomal formulationofdoxorubicin.Meth.Enzymol. 391,71–97.doi:10.1016/S0076-6879(05)91004-5 Agemy,L., Sugahara,K.N.,Kotamraju,V.R.,Gujraty,K.,Girard,O.M.,Kono,Y., etal.(2010).Nanoparticle-inducedvascularblockadeinhumanprostatecancer. Blood116,2847–2856.doi:10.1182/blood-2010-03-274258 Ahlers, J.D., andBelyakov, I.M. (2010).Memories that last forever: strategies for optimizingvaccineT-cellmemory.Blood115, 1678–1689. doi: 10.1182/blood- 2009-06-227546 Ahmad,M.,Rees,R.C., andAli,S.A. (2004).Escape fromimmunotherapy:possi- blemechanisms that influence tumorregression/progression.Cancer Immunol. Immunother.53,844–854.doi:10.1007/s00262-004-0540-x Ahrens,E.T.,andBulte, J.W.(2013).Trackingimmunecells invivousingmagnetic resonance imaging.Nat.Rev. Immunol.13,755–763.doi:10.1038/nri3531 Ahrens, E. T., Feili-Hariri, M., Xu, H., Genove, G., and Morel, P. A. (2003). Receptor-mediated endocytosis of iron-oxideparticles provides efficient label- ingofdendriticcells for invivoMRimaging.Magn.Reson.Med.49,1006–1013. doi:10.1002/mrm.10465 Ahrens, E. T., Flores, R., Xu, H., andMorel, P. A. (2005). In vivo imaging plat- form for tracking immunotherapeutic cells.Nat. Biotechnol. 23, 983–987. doi: 10.1038/nbt1121 Al-Hanbali, O., Rutt, K. J., Sarker, D. K., Hunter, A. C., and Moghimi, S. M. (2006). Concentration dependent structural ordering of poloxamine 908 on polystyrenenanoparticlesandtheirmodulatoryroleoncomplementconsump- tion. J.Nanosci.Nanotechnol.6,3126–3133.doi:10.1166/jnn.2006.406 Albertsson,A.-C.(2002).DegradableAliphaticPolyesters.Berlin;London:Springer. Alexis,F.,Pridgen,E.,Molnar,L.K.,andFarokhzad,O.C.(2008).Factorsaffecting the clearance and biodistribution of polymeric nanoparticles.Mol. Pharm. 5, 505–515.doi:10.1021/mp800051m Arbab, A. S., Pandit, S. D., Anderson, S. A., Yocum, G. T., Bur,M., Frenkel, V., et al. (2006).Magnetic resonance imaging and confocalmicroscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis.StemCells24,671–678.doi:10.1634/stemcells.2005-0017 Arbab,A.S.,Yocum,G.T.,Kalish,H., Jordan,E.K.,Anderson,S.A.,Khakoo,A.Y., et al. (2004).Efficientmagnetic cell labelingwithprotamine sulfate complexed to ferumoxides for cellularMRI. Blood 104, 1217–1223. doi: 10.1182/blood- 2004-02-0655 Arbab, A. S., Yocum, G. T., Rad, A. M., Khakoo, A. Y., Fellowes, V., Read, E. J., et al. (2005). Labeling of cells with ferumoxides-protamine sulfate com- plexesdoesnot inhibit functionordifferentiationcapacityofhematopoieticor mesenchymal stemcells.NMRBiomed.18,553–559.doi:10.1002/nbm.991 Aslan, B., Ozpolat, B., Sood, A. K., and Lopez-Berestein, G. (2013). Nanotechnology in cancer therapy. J. Drug Target. 21, 904–913. doi: 10.3109/1061186X.2013.837469 Bachmann,M. F., and Jennings, G. T. (2010). Vaccine delivery: amatter of size, geometry,kineticsandmolecularpatterns.Nat.Rev.Immunol.10,787–796.doi: 10.1038/nri2868 Ballou,B., Ernst, L.A.,Andreko, S.,Harper,T., Fitzpatrick, J.A.,Waggoner,A. S., etal.(2007).Sentinel lymphnodeimagingusingquantumdotsinmousetumor models.Bioconjug.Chem.18,389–396.doi:10.1021/bc060261j Ballou, B., Lagerholm, B. C., Ernst, L. A., Bruchez, M. P., andWaggoner, A. S. (2004). Noninvasive imaging of quantumdots inmice. Bioconjug. Chem. 15, 79–86.doi:10.1021/bc034153y Banchereau, J., Paczesny, S., Blanco, P., Bennett, L., Pascual, V., Fay, J., et al. (2003). Dendritic cells: controllers of the immune system and a newpromise for immunotherapy. Ann. N.Y. Acad. Sci. 987, 180–187. doi: 10.1111/j.1749- 6632.2003.tb06047.x Banchereau, J., Schuler-Thurner, B., Palucka, A. K., and Schuler, G. (2001). Dendritic cells as vectors for therapy.Cell 106, 271–274. doi: 10.1016/S0092- 8674(01)00448-2 Benoit,M. A., Baras, B., andGillard, J. (1999). Preparation and characterization of protein-loaded poly(epsilon-caprolactone) microparticles for oral vaccine delivery. Int. J.Pharm.184,73–84. Berinstein,N.L.,Karkada,M.,Morse,M.A.,Nemunaitis,J.J.,Chatta,G.,Kaufman, H., et al. (2012). First-in-man application of a novel therapeutic cancer vac- cine formulationwith the capacity to inducemulti-functionalT cell responses in ovarian, breast and prostate cancer patients. J. Transl. Med. 10, 156. doi: 10.1186/1479-5876-10-156 Bernsen, M. R., Vaissier, P. E., VanHolen, R., Booij, J., Beekman, F. J., and De Jong,M.(2014).TheroleofpreclinicalSPECTinoncological andneurological researchincombinationwitheitherCTorMRI.Eur. J.Nucl.Med.Mol. Imaging 41(Suppl.1),S36–S49.doi:10.1007/s00259-013-2685-3 Betancourt, T., Byrne, J. D., Sunaryo, N., Crowder, S. W., Kadapakkam, M., Patel, S., et al. (2009). PEGylation strategies for active targeting of PLA/PLGA nanoparticles. J.Biomed.Mater.Res.A91,263–276.doi:10.1002/jbm.a.32247 Biswas, S. K., andMantovani, A. (2010). Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.Nat. Immunol. 11, 889–896. doi:10.1038/ni.1937 Blanco, E., Kessinger, C. W., Sumer, B. D., and Gao, J. (2009). Multifunctional micellar nanomedicine for cancer therapy. Exp. Biol. Med. (Maywood). 234, 123–131.doi:10.3181/0808-MR-250 Bodey, B., Siegel, S. E., and Kaiser, H. E. (2004). Antigen presentation by den- dritic cells and their significance inantineoplastic immunotherapy. InVivo18, 81–100. Bos,R.,Marquardt,K.L.,Cheung,J.,andSherman,L.A.(2012).Functionaldiffer- encesbetweenlow-andhigh-affinityCD8(+)Tcells inthetumorenvironment. Oncoimmunology1,1239–1247.doi:10.4161/onci.21285 Brocchini, S.,Godwin,A.,Balan,S.,Choi, J.W.,Zloh,M., andShaunak,S. (2008). Disulfide bridge basedPEGylationof proteins.Adv.DrugDeliv. Rev. 60, 3–12. doi:10.1016/j.addr.2007.06.014 Budhu,S.,Wolchok,J.,andMerghoub,T.(2014).Theimportanceofanimalmodels intumorimmunityandimmunotherapy.Curr.Opin.Genet.Dev.24,46–51.doi: 10.1016/j.gde.2013.11.008 Bulte, J. W., Douglas, T., Witwer, B., Zhang, S. C., Strable, E., Lewis, B. K., et al. (2001). Magnetodendrimers allow endosomal magnetic labeling and in vivo trackingof stemcells.Nat. Biotechnol.19, 1141–1147. doi: 10.1038/nbt 1201-1141 Bulte, J. W., and Kraitchman, D. L. (2004). Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 17, 484–499. doi: 10.1002/nbm.924 Burnet,M. (1957).Cancer; a biological approach. I. Theprocesses of control.Br. Med. J.1,779–786. Bussolati, B., Grange, C., and Camussi, G. (2011). Tumor exploits alternative strategiestoachievevascularization.FASEBJ.25,2874–2882.doi:10.1096/fj.10- 180323 Cai,W., Chen, K., Li, Z. B., Gambhir, S. S., andChen, X. (2007). Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J.Nucl.Med.48,1862–1870.doi:10.2967/jnumed.107.043216 Cai,W., andChen, X. (2007). Nanoplatforms for targetedmolecular imaging in livingsubjects.Small3,1840–1854.doi:10.1002/smll.200700351 Cai,W., Shin,D.W., Chen,K., Gheysens,O., Cao,Q.,Wang, S. X., et al. (2006). Peptide-labelednear-infraredquantumdots for imaging tumor vasculature in livingsubjects.NanoLett.6,669–676.doi:10.1021/nl052405t Cai,X.,Yin,Y.,Li,N.,Zhu,D.,Zhang,J.,Zhang,C.Y.,etal. (2012).Re-polarization of tumor-associated macrophages to pro-inflammatory M1macrophages by microRNA-155. J.Mol.CellBiol.4,341–343.doi:10.1093/jmcb/mjs044 www.frontiersin.org November2014 |Volume2 |Article105 | 86